Status:

COMPLETED

Intravitreal Bevacizumab for Neovascular Glaucoma

Lead Sponsor:

Shahid Beheshti University of Medical Sciences

Conditions:

Neovascular

Glaucoma

Eligibility:

All Genders

10-80 years

Phase:

NA

Brief Summary

Several studies have confirmed high levels of vascular endothelial growth factor (VEGF) in eyes with neovascular glaucoma (NVG). The role of VEGF inhibitors in regression of other neovascular disorder...

Eligibility Criteria

Inclusion

  • Clinical diagnosis of NVG
  • Vision less than 20/200
  • age 10-80 years

Exclusion

  • Uncontrolled Blood Pressure
  • History of thromboembolism
  • Congestive Heart Failure
  • Renal Failure
  • Pregnancy or Lactation
  • Active ocular or periocular infection
  • No light perception

Key Trial Info

Start Date :

April 1 2006

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 1 2007

Estimated Enrollment :

26 Patients enrolled

Trial Details

Trial ID

NCT00384631

Start Date

April 1 2006

End Date

March 1 2007

Last Update

February 15 2008

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Labbafinejad Medical Center

Tehran, Tehran Province, Iran, 16666

Intravitreal Bevacizumab for Neovascular Glaucoma | DecenTrialz